TWiV 1074: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses the outcomes of SARS-CoV-2, influenza and respiratory syncytial virus infection in pediatric communities under the age of 18 years, the treatment of infants with the human monoclonal anti-respiratory syncytial virus antibody to prevent hospitalizations, most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, how the SARS-CoV-2/COVID-19 pandemic affected school attendance and child healthcare, how exposure length influenced transmission of SARS-CoV-2, how the durability of the anti-SARS-CoV-2 antibody response to protect against virus re-infection, if administration of oral antiviral therapy affected viral rebound in either the unvaccinated or vaccinated populations, as well as a reminder of the ineffectiveness of antibiotics for treating COVID-19 and the effect of vaccination on post-COVID conditions in children between 5-17 years old. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Pediatric outcomes SARS-CoV-2, flu, RSV (JAMA Peds.) SARS-CoV-2 vs Flu  (Wired) Anti-RSV antibody treatment for infants (NEJM) Respiratory  disease surveillance (CDC) RSV surveillance  (CDC) RSV national trend (CDC) Influenza/flu surveillance  (CDC) COVID-19  hospital admissions (CDC) COVID-19 national trend (CDC) COVID-19 wastewater testing (biobot) COVID-19 school attendance (JP...
Source: This Week in Virology - MP3 Edition - Category: Virology Authors: Source Type: podcasts